Severe Combined Immunodeficiency (SCID) Market

Market Overview:

The severe combined immunodeficiency (SCID) market reached a value of USD 216.5 Million across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 572.2 Million by 2035, exhibiting a growth rate (CAGR) of 9.27% during 2025-2035.

The severe combined immunodeficiency (SCID) market has been comprehensively analyzed in IMARC's new report titled "Severe Combined Immunodeficiency (SCID) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035". Severe combined immunodeficiency (SCID) is a rare genetic illness defined by abnormal development of functional T and B cells as a result of many genetic abnormalities that induce varying clinical manifestations. SCID patients are typically impacted by severe bacterial, viral, or fungal infections early in life, and they frequently present with interstitial lung disease, chronic diarrhea, and failure to thrive. Ear infections, recurrent Pneumocystis jirovecii (formerly carinii) pneumonia, and widespread oral candidiasis are prevalent. Individuals suffering from this ailment often have chronic cough, wheezing, or difficulty breathing due to lung infections. The major diagnostic test for SCID is a blood test known as the T-cell receptor excision circle (TREC), which is normally conducted as part of newborn screening and evaluates the presence of T cells. The healthcare professional might also recommend flow cytometry for real-time analysis of cellular composition, cell signaling, and other relevant immunological pathways. Furthermore, genetic testing is performed to identify mutations in specific genes that are associated with the condition.

The escalating prevalence of genetic mutations that affect the development and function of immune cells, specifically T cells and B cells, leading to a severely compromised immune system is primarily driving the severe combined immunodeficiency (SCID) market. In addition to this, the inflating utilization of stem cell transplant, since it replaces a patient's faulty immune system with healthy stem cells from a donor, essentially building a new functional immune system for the individuals, is also creating a positive outlook for the market. Moreover, the widespread adoption of intravenous immunoglobulin (IVIg), which provides passive immunity by delivering antibodies to help fight infections while the patient undergoes a stem cell transplant, is further bolstering the market growth. Apart from this, the rising usage of enzyme replacement therapy, on account of its several benefits, like increased lymphocyte counts, reduced infection risk, and delayed disease progression, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of gene editing techniques to precisely target and correct the mutated gene within a patient's hematopoietic stem cells is expected to drive the severe combined immunodeficiency (SCID) market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the severe combined immunodeficiency (SCID) market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for severe combined immunodeficiency (SCID) and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the severe combined immunodeficiency (SCID) market in any manner.

Drugs:

Revcovi (Elapegademase) functions by providing an external source of the adenosine deaminase (ADA) enzyme, which is defective in ADA-SCID patients. This allows for the breakdown of harmful adenosine and deoxyadenosine nucleotides, resulting in an increase in lymphocyte count and enhanced immunological function. Essentially, restoring the missing ADA enzyme in the body to rebuild normal immunological function.

Simoladagene autotemcel, developed by Orchard Therapeutics, treats severe combined immunodeficiency using gene therapy. It works by removing a patient's hematopoietic stem cells, genetically altering them to fix the faulty gene that causes SCID, and then reinfusing the corrected cells back into the patient, allowing them to create functional immune cells and restore immune system function. Essentially, it restores the patient's stem cells, resulting in healthy immune cells rather than the malfunctioning ones generated by the SCID mutation.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the severe combined immunodeficiency (SCID) market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the severe combined immunodeficiency (SCID) market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current severe combined immunodeficiency (SCID) marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the severe combined immunodeficiency (SCID) market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the severe combined immunodeficiency (SCID) market across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the severe combined immunodeficiency (SCID) market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of prevalent cases (2019-2035) of severe combined immunodeficiency (SCID) across the seven major markets?
• What is the number of prevalent cases (2019-2035) of severe combined immunodeficiency (SCID) by age across the seven major markets?
• What is the number of prevalent cases (2019-2035) of severe combined immunodeficiency (SCID) by gender across the seven major markets?
• How many patients are diagnosed (2019-2035) with severe combined immunodeficiency (SCID) across the seven major markets?
• What is the size of the severe combined immunodeficiency (SCID) patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2025-2035) across the seven major markets?
• What are the key factors driving the epidemiological trend of severe combined immunodeficiency (SCID)?
• What will be the growth rate of patients across the seven major markets?

Severe Combined Immunodeficiency (SCID): Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for severe combined immunodeficiency (SCID) drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the severe combined immunodeficiency (SCID) market?
• What are the key regulatory events related to the severe combined immunodeficiency (SCID) market?
• What is the structure of clinical trial landscape by status related to the severe combined immunodeficiency (SCID) market?
• What is the structure of clinical trial landscape by phase related to the severe combined immunodeficiency (SCID) market?
• What is the structure of clinical trial landscape by route of administration related to the severe combined immunodeficiency (SCID) market?